XFOR - X4 Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

11.99M

Cash

141.3M

Avg Qtr Burn

-21.58M

Short % of Float

8.20%

Insider Ownership

0.85%

Institutional Own.

68.64%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Mavorixafor (CXCR4 inhibitor) Details WHIM Syndrome	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavorixafor (CXCR4 inhibitor) Details Severe Congenital Neutropenia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavorixafor (CXCR4 inhibitor) + ibrutinib Details Waldenstrom macroglobulinemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavorixafor (CXCR4 inhibitor) Details Renal cell carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.